Amplifon S.p.A. (0N61)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 12.80 |
|---|---|
| 52-week range | 7.63 – 15.42 |
| Return, 1 month / 3 months | +9.8% / +15.5% |
| Return, 1 year / 3 years | −10.1% / −51.3% |
| Trend | Uptrend |
| RSI (14) | 63 |
| Volatility (1 year) | 41.5% |
| Worst drawdown (1 year) | -49.0% |
| Average daily value traded | 0.94M EUR |
| Dividend yield | 2.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Amplifon is an Italian hearing care company based in Milan. It provides hearing aids and related services through a network of hearing centres and retail outlets, serving people with hearing loss across many countries. The company fits hearing devices, offers consultations and aftercare, and works with manufacturers to supply the products it dispenses. Its customers are mainly individual consumers, and it also serves through partnerships with healthcare providers and insurers in the markets where it operates.
On this site Amplifon S.p.A. appears as a stock on the London Exchange (UK), code 0N61, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Amplifon S.p.A. (0N61) trades on the London Exchange in UK. It last closed at EUR 12.80 on 21 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 1,840 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.1% and over the last three months it rose 15.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 67 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 14.0% | ||
| From 52-week high | -16.5% | ||
| Momentum | 65 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 15.5% | ||
| 6-month return | 33.4% | ||
| 12-month return, skipping the last month | -18.1% | ||
| Stability (higher is calmer) | 30 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -49.0% | ||
| Liquidity | 52 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.94M EUR | ||
| Zero-volume days | 1.7% | ||
| Income | 52 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.3% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +4.1% |
|---|---|
| 1 month | +9.8% |
| 3 months | +15.5% |
| 6 months | +33.4% |
| 1 year | −10.1% |
| 3 years | −51.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 11.98 / 11.23 |
|---|---|
| Golden / death cross (60 days) | Golden, 31 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.39 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | EUR 0.2900 |
| 19 May 2025 | EUR 0.2900 |
| 20 May 2024 | EUR 0.2900 |
| 22 May 2023 | EUR 0.2900 |
| 23 May 2022 | EUR 0.2600 |
| 24 May 2021 | EUR 0.2200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.